Shanghai, April 14, 2024 – The four-day 89th China International Medical Equipment Fair (CMEF) came to a successful close at the National Exhibition and Convention Center (Shanghai). Widely regarded as a barometer of the medical device industry, this year's CMEF brought together numerous industry leaders from around the world to exchange ideas and share innovations in medical technology.

During the exhibition, the Cygnus Bio team engaged in in-depth discussions and exchanges with experts and peers from across the globe. They not only shared the company's latest research achievements in gene sequencing technology but also held lively debates on the application and development of gene sequencing technologies.

As a high-tech Chinese enterprise integrating R&D, translation, production, and marketing of genetic technologies, Cygnus Bio has always been committed to independent research and development in the gene sequencing industry, striving to create sequencing system products with full proprietary intellectual property rights. At this exhibition, Cygnus Bio showcased its GS100 Sequencing System and supporting products, earning widespread acclaim from attendees.

The independently developed GS100 Sequencing System leverages one‑step fluorogenic sequencing chemistry and triple error‑correcting code (ECC) sequencing technology. It features high accuracy, fast processing, dual‑mode operation, and flexible deployment. With data quality reaching as high as Q40 (accuracy > 99.99%), the system can directly detect low‑frequency mutations. It is also compatible with mainstream commercial libraries, covering key genetic testing scenarios in both medical and research settings.